National and Kapodistrian University of Athens
Πρόληψη της καρδιοτοξικότητας από ανθρακυκλίνες με β-αποκλειστές και Α-ΜΕΑ σε ασθενείς με Hodgkin και non-Hodgkin λεμφώματα
Abstract
dc:descriptionBackground: Doxorubicin is the most potent and efficacious antineoplastic agent. However, the severe cardiotoxic effects of the anthracyclines limit their beneficial effect on survival in cancer patients. We designed this randomized trial to investi-gate the possible cardioprotective effects of metoprolol (b-adrenergic antagonist) and enalapril (angiotensin-converting enzyme inhibitor) combined with doxorubi-cin-based chemotherapy in patients with lymphoma.Subjects and methods: Patients with lymphoma were randomly assigned to re-ceive doxorubicin-based chemotherapy with metoprolol (group 1) or enalapril (group 2) or no additional treatment (group 3). Doppler echocardiographic exami-nations were performed and repeated measurements of left ventricular function were recorded. The primary end-points were: 1) the occurrence of doxorubicin-induced clinical or subclinical cardiotoxicity in lymphoma patients during the first year of chemotherapy (early cardiotoxicity), after concomitant administration with metoprolol or enalapril or no concomitant treatment and 2) the incidence of late cardiotoxicity (>1 year of follow-up including treatment period). Clinical cardiotoxic-ity was defined as the presence of congestive heart failure. Subclinical cardiotoxic-ity was classed as: 1) a difference of 10% between the left ventricular injection fraction values at each visit and the baseline value, and left ventricular ejection fraction <50% and 2) a change in systolic and diastolic left ventricular ejection frac-tion from the baseline.Results: One hundred twenty five patients were eligible for analysis (65 men), mean age 49 years (± SD 17.85 years). Forty two patients were randomly assigned to receive metoprolol, 43 to receive enalapril and 42 no treatment. Mean follow-up was 31 months (SD ± 17.7 months). One hundrend nine patients completed one year of follow-up (early cardiotoxicity), 64 patients 2 years, and 45 patients 3 years. Congestive heart failure developed in 6 (4.8%) patients. One patient received metoprolol, 2 received enalapril and 3 received no concomitant treatment (2=1.178, p=0.555). We observed 20 (16%) cases of early cardiotoxicity and 8 (7.3%) cases of late cardiotoxicity. No association was found between the presence of cardiotoxicity and concomitant treatment, type of lymphoma, gender, age, smoking status, or body mass index. The mean changes for all echocardiographic variables between groups did not differ significantly at any measuring time up to the early cardiotoxicity endpoint 12 months after baseline. The findings for late cardiotoxicity were similar. Only the E/A ratio of diastolic function was statistically significantly increased in the metoprolol group 30 and 42 months after treatment initiation (p=0.003 and p=0.005 respectively). The 17 adverse events recorded were distributed evenly across study groups. Metoprolol and enalapril were tolerated well in most patients.Conclusions: Doxorubicin in conventional doses for the treatment of lymphoma patients did not alter the systolic left ventricular function during the whole follow-up period. Metoprolol had a positive impact in diastolic left ventricular function.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Georgakopoulos, Petros
- Γεωργακόπουλος, Πέτρος
Subjects
dc:subject × 20Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/34814